Skip to search formSkip to main contentSkip to account menu

CGP 28014

Known as: CGP-28014 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Inhibitors of catechol‐O‐methyltransferase sensitize mice to pain
BACKGROUND AND PURPOSE Catechol‐O‐methyltransferase (COMT) inhibitors are used in Parkinson's disease in which pain is an… 
1994
1994
Clinical Potential of Catechol-OMethyltransferase (COMT) Inhibitors as Adjuvants in Parkinson’s Disease
SummaryA series of new and selective catechol-O-methyltransferase (COMT) inhibitors have been developed. Entacapone, nitecapone… 
1993
1993
Modulation of rat brain endogenous dopamine metabolism by new inhibitors of catechol O-methyltransferase.
1993
1993
Effects of CGP 28014 on the in vivo release and metabolism of dopamine in the rat striatum assessed by brain microdialysis
The effects on rat striatal dopamine (DA) metabolism of systemic and local administration of CGP 28014, an inhibitor of catechol… 
1993
1993
COMT inhibitors and metabolism of fluorodopa enantiomers in aggregating cell cultures
SummaryOrganotypic primary cell cultures of fetal rat brain were used as a model system to study the effect of COMT inhibitors on… 
1990
1990
CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure
SummaryCGP 28014 (N-(2-pyridone-6-yl)-N′,N′-di-n-propylformamidine) or its methanesulfonate salt CGP 28014 A was suspected to be… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)